コンテンツへスキップ
Merck

M-128

Supelco

ミルタザピン 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C17H19N3
CAS番号:
分子量:
265.35
EC Number:
UNSPSCコード:
41116107
NACRES:
NA.24

グレード

certified reference material

品質水準

形状

liquid

特徴

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

メーカー/製品名

Cerilliant®

濃度

1.0 mg/mL in methanol

テクニック

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

アプリケーション

clinical testing

フォーマット

single component solution

保管温度

−20°C

SMILES記法

CN1CCN2C(C1)c3ccccc3Cc4cccnc24

InChI

1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

InChI Key

RONZAEMNMFQXRA-UHFFFAOYSA-N

詳細

Mirtazapine is a tetracyclic antidepressant marketed under the trade names Remeron®, Avanza, or Zispin for treatment of depression. This Certified Spiking Solution® is suitable for LC/MS or GC/MS applications in forensic analysis, clinical toxicology, or urine drug testing.

アプリケーション


  • Mirtazapine research solution for CNS studies: A study on the nose-to-brain delivery of mirtazapine via lipid nanocapsules highlights its potential for enhanced CNS targeting, offering a promising approach for treating neurological conditions. This method aims to improve the bioavailability and therapeutic effectiveness of mirtazapine, showcasing its utility in pharmacokinetic research and CNS depressant studies (Ibrahim et al., 2024).

  • Mirtazapine liquid formulation for orally disintegrating tablets: Research into developing a novel direct compressible co-processed excipient for the formulation of mirtazapine orally disintegrating tablets emphasizes its importance in enhancing patient compliance and dosing accuracy. This study demonstrates mirtazapine′s role in pharmaceutical formulations, ensuring rapid onset of action which is critical in acute management of depressive episodes (Loke et al., 2024).

  • High-purity mirtazapine liquid for neurotransmitter research: A review linking stress, depression, and insulin resistance explores the systemic effects of chronic inflammation and the role of treatments like mirtazapine. This research underscores the importance of mirtazapine in understanding the biochemical pathways involved in chronic mental health disorders and their somatic comorbidities (Mehdi et al., 2023).

  • Stable mirtazapine formulation for opioid withdrawal treatment: Mirtazapine is explored as a one-stop strategy for the treatment of opioid withdrawal symptoms, highlighting its efficacy in reducing withdrawal severity and potentially lowering the dependency on traditional opioid replacement therapies. This application provides insights into mirtazapine′s versatility in treating complex drug dependencies (Lalani et al., 2023).

  • Mirtazapine aqueous solution for pharmacokinetic profiling: Research on the simultaneous separation and determination of several chiral antidepressants, including mirtazapine, in wastewater by two-dimensional liquid chromatography offers critical insights into environmental exposure and bioaccumulation risks. This study is pivotal for environmental safety and pharmaceutical dispersion monitoring, reflecting mirtazapine′s impact beyond clinical settings (Zhong et al., 2023).

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Remeron is a registered trademark of MSD
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

ピクトグラム

FlameSkull and crossbonesHealth hazard

シグナルワード

Danger

危険有害性情報

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

ターゲットの組織

Eyes

保管分類コード

3 - Flammable liquids

WGK

WGK 1

引火点(°F)

49.5 °F - closed cup

引火点(℃)

9.7 °C - closed cup


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

消防法

第4類:引火性液体
アルコール類
危険等級II

Jan Code

M-128-CC:
M-128-1ML:4548173335629


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Seda G Sagdinc et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 104, 222-234 (2012-12-26)
Mirtazapine (±)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine is a compound with antidepressant therapeutic effects. It is the 6-aza derivative of the tetracyclic antidepressant mianserin (±)-2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine. The FT-IR and FT-Raman spectra of mirtazapine have been recorded in 4000-400 cm(-1) and 3500-10 cm(-1), respectively. The optimized geometry
Xiaoyu Liu et al.
Neurochemical research, 38(9), 1973-1979 (2013-07-10)
Chemotherapic drugs may elicit acute or chronic peripheral neuropathies. Mirtazapine, as an antidepressant, is also used for the treatment of neuropathic pain. The current study aimed to investigate the effect of mirtazapine on the oxaliplatin-induced neuropathy in rats as well
Steven M Graves et al.
Pharmacology & therapeutics, 136(3), 343-353 (2012-09-11)
Understanding substance use disorders (SUDs) and the problems associated with abstinence has grown in recent years. Nonetheless, highly efficacious treatment targeting relapse prevention has remained elusive, and there remains no FDA-approved pharmacotherapy for psychostimulant dependence. Preclinical and clinical investigations assessing
E L Theunissen et al.
Clinical pharmacology and therapeutics, 93(6), 493-501 (2013-04-17)
The aim of this study was to assess the effects of a novel antidepressant, vortioxetine 10 mg, on driving, cognitive, and psychomotor performance in 24 healthy subjects in a double-blind, placebo-controlled, three-way crossover design. Mirtazapine 30 mg was included as an active
Renee Romeo et al.
The British journal of psychiatry : the journal of mental science, 202, 121-128 (2012-12-22)
Depression is a common and costly comorbidity in dementia. There are very few data on the cost-effectiveness of antidepressants for depression in dementia and their effects on carer outcomes. To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)